December 14, 2021

Division of Dockets Management (HFA-305)
Food and Drug Administration
5630 Fishers Lane, Rm. 1061
Rockville, MD 20852

Submitted Electronically

Subject: Request for Withdrawal of Citizen Petition FDA-2019-P-2687

Dear Sir/Madam,

Aurobindo Pharma Ltd. herewith requests withdrawal of our Citizen Petition FDA-2019-P-2687 (originally received by the Agency on June 3, 2019) pursuant to 21 CFR §10.30(g).

Our petition had requested that the Agency assign a TE Code of "AP" to Aurobindo Pharma Ltd.'s NDA 209552, Argatroban in Sodium Chloride Injection, 50 mg/50 mL.

This withdrawal request is being submitted on behalf of the petitioner Aurobindo Pharma Ltd.

Please contact the undersigned at AuroMedics Pharma LLC, 279 Princeton-Hightstown Road, East Windsor, NJ 08520, if you have any questions regarding this submission.

Sincerely,
AuroMedics Pharma LLC
(U.S. Agent for Aurobindo Pharma Limited)

Vincent P. Andolina

Digitally signed by Vincent P. Andolina
DN: c=US, st=NJ, l=East Windsor, o=AuroMedics Pharma LLC, cn=Vincent P. Andolina, email=vandolina@aurobindousa.com
Date: 2021.12.14 11:12:20 -05'00'

Vincent P. Andolina
Vice President, Regulatory Affairs